PubMed Health⌕ Search

Biomedical subjects

D C Perry

Publications and source records attributed to D C Perry.

At least 37 records · Page 2Linked to original sources

Administration of kainic acid and colchicine alters mu and lambda opiate binding in rat hippocampus.

Quantitative in vitro autoradiography was used to assess the effects of kainic acid (KA) and colchicine (COL) on mu and lambda opiate binding in the rat hippocampus. Rats were treated with either systemic KA, a neurotoxin that damages CA3 pyramidal cells and causes seizures and wet-dog shakes, or intrahippocampal COL to destroy dentate granule cells and their mossy fibers, or both toxins. Moderate levels of mu binding were detected in the pyramidal layer and in the stratum lacunosum-moleculare; binding was greater in the ventral hippocampus. Levels of mu binding were markedly increased in all regions 48 h after treatment with KA. Two weeks after COL treatment, there was a modest decrease in mu binding; COL plus KA gave results similar to COL alone. Dense lambda binding was present over the mossy fibers in the stratum lucidum, but was absent over the pyramidal layer. In contrast to mu binding, lambda binding was greater in the dorsal hippocampus. KA alone had little effect on lambda binding, whereas COL alone caused large decreases. KA plus COL caused even larger decreases in lambda binding, to as much as 85% below control. These results demonstrate that mu and lambda binding are localized to different parts of the hippocampus, respond differently to neurotoxin lesions, and likely serve different roles in this brain region. The number of mu sites is responsive to the release of enkephalin; these receptors appear to be linked to opiate-induced hippocampal seizure activity, especially wet-dog shakes. Lambda sites may serve as autoreceptors on mossy fibers.

Animals↗

[3H]tryptamine binding sites are not identical to monoamine oxidase in rat brain.

Competition binding studies, subcellular distribution, and in vitro autoradiography were employed to compare the binding in rat brain of [3H]tryptamine with two radioligands for monoamine oxidase (MAO), [3H]pargyline, and [3H]1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine ([3H]MPTP). The MAO inhibitors pargyline, clorgyline, and deprenyl all yielded biphasic competition curves versus [3H]tryptamine. At low concentrations, these drugs stimulated binding by protecting the radioligand from MAO oxidation; at considerably higher concentrations, they inhibited binding by direct competition at the [3H]tryptamine binding site. In subcellular distribution studies, [3H]tryptamine was localized preferentially to the synaptosomal fraction, whereas [3H]pargyline showed greater binding to the mitochondrial fraction. Equilibrium binding studies revealed that the potencies of a series of seven compounds at inhibiting [3H]tryptamine binding were completely different from their potencies at inhibiting [3H]MPTP binding. Finally, the autoradiographic distribution of [3H]tryptamine binding in rat brain was different from that of [3H]MPTP and [3H]pargyline. We conclude that the [3H]tryptamine binding site in rat brain is not equivalent to MAO.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗

Bradykinin analogues: differential agonist and antagonist activities suggesting multiple receptors.

Bradykinin analogues with specific antagonist activity in several bioassays were evaluated for effects on [3H]-bradykinin receptor binding sites and inositol phosphate production in neuroblastoma N1E-115 cells. The analogues varied in their affinities for bradykinin receptors in guinea-pig ileum and N1E-115 cell membranes, in their effects on uterine and ileal contractions and in their agonist or antagonist activity on phosphoinositide turnover in N1E-115 cells. These tissue specific effects suggest the presence of multiple bradykinin receptor subtypes.

Animals↗

Barrel rotation in rats induced by intracerebroventricular bradykinin antagonists.

Intracerebroventricular (ICV) administration of bradykinin (BK) analogs containing the substitution DPhe7 produced extreme postural distortions within 2-4 min after injection, eventually causing rats to spin repeatedly around their longitudinal axis. This behavior, called barrel rotation, has been previously reported following ICV administration of several other neuropeptides. Episodes lasted 5-20 min; two deaths occurred at high doses, but no other long-term effects were observed. The quantal ED50 of the prototype compound B4162 (DArg0, Thi5,8 DPhe7BK), was 14.9 nmole; all seven other DPhe7 analogs tested elicited a positive response at 20 nmole. Among analogs not containing DPhe7, only BK elicited any activity (20% response rate), and only at 100 nmoles. Structure-activity considerations indicate that this behavior is not mediated by classical kinin receptors. The response rate to 20 nmole B4162 (81%) did not significantly change after pretreatment with ICV BK (100 nmoles), or IP atropine, haloperidol or phenytoin; whereas pretreatment with ICV captopril and muscimol and IP naloxone, diazepam and phenobarbital all significantly inhibited the response. A GABAergic mechanism may be involved in this peptide behavior.

Animals↗

Autoradiography of lambda binding sites in rat brain.

In vitro receptor autoradiography was used to determine the localization of binding sites with high selectivity for 4,5-epoxymorphinans (lambda sites) in rat brain slices. [3H]Naloxone was used both to label a combination of mu and lambda sites (ligand alone) and to selectively label lambda sites (ligand plus 300 nM diprenorphine added to saturate mu, delta and kappa sites), using incubation conditions optimized for binding to lambda sites. Computerized densitometric analysis confirmed the ligand specificity profile and ionic sensitivity seen for lambda sites in previous homogenate studied. The proportion of mu and lambda sites labeled by [3H]naloxone varied among different brain regions examined. The labeling in the cerebellum, the accessory olfactory bulb and the mossy fiber path of the hippocampus was almost entirely lambda in nature under the conditions employed. A number of regions showed varying proportions of lambda and mu sites, including the cortex, the amygdala, substantia gelatinosa and several thalamic nuclei. Regions labeled by [3H]naloxone containing little or no lambda binding included the striatal patches, the habenula, the substantia nigra and the inferior colliculus. Identification of brain regions with unique lambda site content may facilitate the search for its potential biological function.

Animals↗

[3H]tryptamine autoradiography in rat brain and choroid plexus reveals two distinct sites.

In vitro autoradiographic techniques were used to examine the distribution of [3H]tryptamine binding sites in rat brain. The gross distribution and pharmacological characteristics of binding to brain sections resembled those seen in homogenate studies. Binding sites were found throughout the brain, with a preponderance of sites in the forebrain and limbic structures; highest levels were seen in the choroid plexus and the interpeduncular nucleus. Other regions exhibiting high levels of [3H]tryptamine binding include the cortex (especially lamina I), caudate putamen, hippocampus, anterior olfactory nucleus, olfactory tubercle, nucleus accumbens, amygdala, superior colliculus (superficial gray layer), locus ceruleus, the nucleus of the solitary tract and the pineal body. Although there were similarities in this distribution to that for binding sites of [3H]5-hydroxytryptamine ([3H]serotonin), the overall patterns were distinct. The binding site for [3H] tryptamine in the choroid plexus (termed T-2) was pharmacologically distinct from that in the rest of the brain (termed T-1); several compounds, including kynuramine, were potent inhibitors of [3H]tryptamine binding at the brain site, but not at the choroid plexus site. [3H]Serotonin also labels a site in the rat choroid plexus; this site was different from both [3H]tryptamine sites. Knowledge of the distribution of tryptamine binding sites in the brain will aid in efforts to ascertain the function of these sites.

Animals↗

Identification of bradykinin in mammalian brain.

Bradykinin-like activity was purified from acetic acid extracts of saline-perfused rat brains by gel filtration chromatography and two reverse-phase HPLC systems capable of resolving bradykinin from lysyl-bradykinin and other bradykinin analogs and fragments. Addition of [3H]bradykinin to extracts permitted calculation of recoveries and monitoring of chromatographic fractions. Fractions were examined by radioimmunoassay using a potent and highly specific antiserum raised against bradykinin-human albumin conjugates in rabbits. Bradykinin receptor-active material was also measured by radioreceptor assay using guinea pig ileum, as well as by a bioassay with the estrous rat uterus. Active material chromatographed as authentic bradykinin in all systems. Levels of 0.6 pmol/g whole rat brain were detected, with eight times higher levels in the hypothalamus. Activity increased up to 10-fold following treatment with trypsin; treatment with alpha-chymotrypsin or angiotensin-converting enzyme substantially reduced activity. Similar levels and distribution of bradykinin-like activity were also detected in guinea pig brain extracts. These data substantiate the existence of authentic bradykinin in mammalian brain.

Animals↗

[3H]diprenorphine receptor binding in vivo and in vitro.

In order to investigate opiate receptor binding in vivo, [3H]diprenorphine was given s.c. to rats, and the tracer specifically bound to membraneous high affinity sites was determined with a rapid filtration technique after brain homogenization. Bound [3H]diprenorphine accounted for 70% of the total brain activity after tracer doses. The in vivo binding sites were saturable at 25-30 pmol/g brain. Fifty percent occupancy of the [3H]diprenorphine binding sites in vivo occurred at a dose (10-15 micrograms/kg) that is similar to the antagonistic ED50 of diprenorphine for reversing morphine analgesia. The in vitro binding capacity for [3H]diprenorphine was also approximately 30 pmol/g brain in fresh untreated Tris buffer brain homogenate; however, extensive homogenate dilution or standard membrane washing procedures resulted in a reduction of the [3H]diprenorphine binding site population to 13-22 pmol/g. These results indicate that the opiate receptor system is modified in vitro. Previous studies have shown that the [3H]diprenorphine tracer is retained at cerebral binding sites over several hours in vivo. A diffusion boundary model was proposed to account for the dose dependent tracer retention. In order to investigate the mechanism of the in vivo binding kinetics, [3H]diprenorphine dissociation was measured in brain homogenates after in vivo labeling, immediately following sacrifice of the animals to minimize in vitro artefacts. No differences were found in the dissociation curves at 'infinite' homogenate dilution in the presence or absence of saturating diprenorphine concentrations under various ionic incubation conditions. This result argues against cooperative binding. It is consistent with the hypothesis that the [3H]diprenorphine tracer is retained in vivo because of a diffusion boundary next to the binding sites (receptor micro-compartment) that is destroyed during brain homogenization.

Animals↗

Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model.

The in vivo accumulation and retention of the opiate antagonist tracers [3H]diprenorphine and [3H]naloxone at cerebral opiate receptor sites in rats exceed that expected from their known in vitro receptor affinities. The [3H]diprenorphine serum and brain levels can be stimulated with a pharmacokinetic model that contains the receptors in a micro-compartment. The receptor micro-compartment consists of a population of binding sites next to a diffusion boundary which restricts ligand diffusion away from the receptor. Such an arrangement introduces a delay in the binding equilibrium of potent antagonists with the receptor sites and an increase in the apparent in vivo receptor affinity at subsaturating doses of the ligand; at saturating ligand concentrations these functions of the receptor micro-compartment are abolished. A physiological interpretation of the receptor micro-compartment could be the location of clustered opiate receptor sites on the exterior cell surface next to the synaptic cleft as the diffusion boundary. This kinetic approach involving a combination of pharmacokinetics and drug-receptor interactions permits the quantitative analysis of receptor site availability in the intact animal. Our results support the hypothesis that only one receptor population affects the in vivo disposition of the antagonist tracers, while they do not exclude the presence of low affinity binding sites that have been observed with the use of [3H]naloxone in vitro. Moreover, the binding site population observed in vivo may be responsible for mediating opiate agonist analgesia.

Animals↗

Morphine persistence in rat brain and serum after single doses.

The disposition of morphine in rat brain and serum was determined over 48 hr after subcutaneous doses. Free morphine was measured by a specific assay using 3H-labeling together with high-pressure liquid chromatography separation, with a sensitivity of 1 nM (0.3 ng of morphine per ml). This study revealed the persistence of free morphine in nanomolar concentrations over at least 24 hr after a single analgesic dose. The terminal half-life of morphine elimination was 5 hours. Total radioactivity was retained in the body at much higher concentrations. Similar disposition of [C-1-3H]morphine and [N-14CH3] morphine ruled out any major metabolic alterations at these positions, including N-demethylation. Irreversible binding to insoluble tissue components, which has previously been linked to tolerance, was observed only to the extent of less than 20% of total tissue radioactivity and was not unique to brain tissue. The persistence of morphine and its metabolites may be related to protracted opiate effects such as withdrawal symptoms after addiction.

Animals↗

Global cerebral ischemia and reperfusion alters NMDA receptor binding in canine brain.

We employed a canine model to test whether binding to the N-methyl-D-aspartate (NMDA) class of glutamate receptor channels is altered by global cerebral ischemia and/or reperfusion. Ischemia was induced by 10-min cardiac arrest, followed by restoration of spontaneous circulation for periods of 0, 0.5, 2, 4, and 24 h. In vitro autoradiography was performed on frozen brain sections with three radioligands: [3H]glutamate (under conditions to label the NMDA site), [3H]glycine, and [3H]MK-801. Modest decreases in [3H]glutamate and [3H]MK-801 binding were seen in several regions of hippocampus, and parietal and temporal cortex at early times after reperfusion, with values returning toward control by 24 h. In the striatum, a different pattern was seen: [3H]glutamate and [3H]MK-801 binding increased 50-200% at 0.5-4 h after the start of reperfusion, returning toward control levels by 24 h. These increases correlate with findings of increased sensitivity to NMDA-stimulated release of dopamine from striatal tissue in the same model (Werling et al., 1993), and suggest that changes in tissue receptors may contribute to the selective vulnerability to ischemic damage during the first hours following reperfusion.

Animals↗

Effects of traumatic brain injury in rats on binding to forebrain opiate receptor subtypes.

Sprague-Dawley rats were subjected to a moderate level (2.2 atm) of traumatic brain injury (TBI) using fluid percussion. Injured animals were allowed to survive posttrauma for periods of 5 min, 3 h, and 24 h. The effect of TBI on binding to forebrain opiate receptors was assessed using quantitative receptor autoradiography, and compared to a sham control group. Binding of [3H]DAGO to mu receptors in neocortex and the CA1 pyramidal layer of the hippocampus was significantly decreased in the 24-h group (p less than 0.05). [3H]Bremazocine binding to kappa receptors was unchanged at 5 min and 24 h, but showed large decreases 3 h after TBI in the CA1 pyramidal layer (65%, p less than 0.05) and dentate gyrus (43%, p less than 0.05). Levels of delta binding (measured with [3H]DSLET) and lambda binding (measured with [3H]naloxone) were unaffected by TBI. These data support previous suggestions of a role for endogenous opioids in TBI, and provide further evidence that mu and kappa opioid receptor subtypes in neocortex and hippocampus may have different functions in TBI.

Amino Acid Sequence↗

In vivo binding of 3H-etorphine in morphine-dependent rats.

The opiate agonist 3H-etorphine was used to search for potential changes in in vivo opiate receptor binding in rats following chronic exposure to morphine sulfate. A rapid filtration method was employed to allow assessment of in vivo binding; receptor dissociation in vitro following in vivo labeling was also measured. No significant differences in total binding were seen with addicted animals, naive controls and naive animals pre-injected with morphine, at two different 3H-etorphine doses. In vitro dissociation under several conditions also yielded no differences. However, the rate of in vitro dissociation in the presence of both Na+ and a guanine nucleotide showed a small but significant decrease in dependent animals, suggesting a possible impairment of receptor effector coupling with morphine addiction.

Animals↗